X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TTX-MC138 is an antisense oligonucleotide that targets microRNA-10b, it consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit microRNA-10b. It is being evaluated for advanced solid tumors.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
The collaboration aims to support TransCode’s lead therapeutic candidate, TTX-MC138, which utilizes antisense technology in the treatment of metastatic cancer. Currently, it is undergoing assessment in an early-stage clinical trial.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 29, 2024
Details:
The net proceeds will be used for the clinical development of TTX-MC138 consisting of antagomirs against miRNA-10b conjugated to a unique delivery platform that focuses on the treatment of cancer.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.25 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 22, 2024
Details:
The net proceeds will be used for the clinical development of TTX-MC138 consisting of antagomirs against miRNA-10b conjugated to a unique delivery platform that focuses on the treatment of cancer.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 18, 2024
Details:
TTX-MC138 is an antisense oligonucleotide that targets microRNA-10b, it consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit microRNA-10b. It is being evaluated for metastatic pancreatic cancer.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
The company intends to use the net proceeds for one or more clinical trials with TTX-MC138, an antisense oligonucleotide targeting miR-10b and under investigation for the treatment of various metastatic cancers, including related investigational new drug enabling studies.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Details:
The Company intends to use the net proceeds for one or more clinical trials with TTX-MC138, an antisense oligonucleotide that targets microRNA-10b, its lead therapeutic candidate, including related investigational new drug enabling studies.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 30, 2023
Details:
The net proceeds of from this offering will be used for product development activities, including one or more clinical trials with TTX-MC138, including related IND-enabling studies, and for working capital and other general corporate purposes.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 26, 2023
Details:
TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit the oncogenic RNA, microRNA-10b. MiRNA-10b is described as the master regulator of cancer progression in a number of advanced solid tumors.
Lead Product(s): TTX-MC138
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid specifically designed to inhibit the oncogenic RNA, microRNA-10b. MiRNA-10b has been described as the master regulator of cancer progression in a number of advanced solid tumors.
Lead Product(s): TTX-MC138-NODAGA-Cu64
Therapeutic Area: Oncology Product Name: TTX-MC138
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
